Market Outlook
The India Gene Therapy Market is witnessing a transformative shift, marked by rapid advancements in biotechnology and increased focus on personalized medicine. Valued at USD 472.24 million in 2024, the market is projected to reach USD 1,203.38 million by 2030, reflecting the growing emphasis on cutting-edge therapeutic approaches. The rising burden of genetic disorders, rare diseases, and certain cancers has catalyzed the need for targeted treatments that gene therapy uniquely offers. Moreover, increasing R&D investments, expansion of clinical trial frameworks, and growing partnerships between biotech firms and academic institutions have further accelerated market growth.
Government support for genetic research, favorable regulatory frameworks, and increased public-private funding initiatives are helping to solidify India's position in the global gene therapy landscape. Additionally, the cost trajectory for genetic sequencing and vector manufacturing is showing signs of decline, making treatments gradually more accessible. India’s robust pharmaceutical manufacturing ecosystem and a large patient pool with unmet clinical needs are also key enablers of market expansion. As more therapies secure regulatory approvals and enter commercial markets, the India Gene Therapy Market is poised to emerge as a high-potential segment within the broader life sciences industry.
Browse market data Figures spread through 108 Pages and an in-depth TOC on "India Gene Therapy Market” - https://www.techsciresearch.com/report/india-gene-therapy-market/27691.html
Market Driver Analysis
One of the strongest drivers for the India gene therapy market is the rising prevalence of genetic disorders and rare diseases, many of which lack effective conventional treatments. India reports approximately 1.7 million births annually affected by congenital abnormalities, with 70 million people living with rare diseases such as thalassemia, hemophilia, and spinal muscular atrophy (SMA). For instance, thalassemia affects over 100,000 individuals, with 10,000–12,000 new cases each year. Additionally, hematologic cancers like leukemia and lymphoma are increasing, with 65,000 new leukemia cases and 30,000 lymphoma cases reported in 2024, particularly among the aging population, which comprises 12.5% of India’s 1.44 billion people (2024 estimate). This growing disease burden underscores the urgent need for advanced cell and gene therapies.
Improved diagnostic tools and genetic screening capabilities are enabling early detection and intervention. Over 350 diagnostic labs in India adopted next-generation sequencing (NGS) platforms by 2025, increasing the detection rate of genetic disorders by 28% compared to conventional methods. For example, prenatal screening for chromosomal abnormalities like Down syndrome has grown by 35% in urban centers such as Bengaluru and Chennai since 2021. These advancements facilitate timely identification of conditions suitable for gene therapy, boosting market demand.
India’s biotech sector is experiencing significant innovation, with a 15% increase in gene therapy-related patent filings from 2023 to 2025, reaching over 1,300 patents. Research institutions like the Indian Institute of Technology (IIT) Bombay and Christian Medical College (CMC) Vellore have driven 60% of these patents, focusing on therapies for sickle cell anemia and Duchenne muscular dystrophy, which affect 1.5 million and 500,000 individuals, respectively. This innovation is supported by a 20% rise in biotech R&D funding, reaching ₹2,500 crore in 2024.
Government-backed initiatives, such as the National Policy for Rare Diseases (NPRD) 2021, are accelerating market growth by prioritizing genomic data integration and subsidized treatment access. The NPRD has allocated ₹60 crore annually to 12 Centers of Excellence (CoEs), which conducted 25 gene therapy trials for diseases like SMA (1 in 8,000 births) and hemophilia in 2024. The Department of Biotechnology (DBT) also invested ₹250 crore in 2024–25 to develop genomic databases, enabling precision medicine for 10 million patients.
Collaborations with global biotech firms are enhancing technology transfer and clinical research. For instance, partnerships between Indian companies like Biocon and global leaders like Gilead Sciences have initiated five CAR-T cell therapy trials for lymphoma in 2025, reducing development costs by 25%. These collaborations have enabled 20 Indian firms to engage in gene therapy R&D, with four therapies (for thalassemia and retinal disorders) nearing regulatory approval as of June 2025. The cumulative effect of these drivers—high disease prevalence, advanced diagnostics, robust innovation, supportive policies, and global partnerships—is fostering an environment conducive to the development, testing, and commercialization of gene therapies tailored to India’s diverse patient demographics, with the market projected to grow at a CAGR of 23% through 2032.
Market Trends Analysis
The India Gene Therapy Market is evolving rapidly, with several key trends defining its trajectory. One notable trend is the increasing adoption of viral vector technologies, particularly adeno-associated viruses (AAVs) and lentiviruses, which are being widely used in ongoing clinical trials and commercial gene therapies. Companies are also investing in next-generation delivery mechanisms, such as CRISPR-based gene editing and non-viral vectors, to enhance treatment precision and minimize immunogenicity risks.
Another significant trend is the growing integration of artificial intelligence and machine learning in gene therapy research. These technologies are being used for mapping gene expressions, optimizing vector design, and predicting patient response. Furthermore, strategic mergers and acquisitions are on the rise, as Indian pharmaceutical companies aim to gain access to intellectual property, manufacturing capabilities, and global clinical networks.
India is also witnessing a surge in academic-industry collaborations, with premier institutions like IITs and AIIMS partnering with biopharma firms to accelerate gene therapy research. Meanwhile, the emergence of specialized biobanks and genomics startups is helping build the necessary infrastructure for long-term development. As gene therapies begin transitioning from experimental use to approved treatments, their adoption in treating hematological malignancies, inherited disorders, and even ocular conditions is expected to gain momentum.
Market Challenges Analysis
Despite its promising growth, the India Gene Therapy Market faces several challenges. High treatment costs remain a significant barrier, often exceeding INR 1 crore per therapy, making access limited to affluent segments or externally funded patients. Additionally, the country still lacks a comprehensive regulatory framework tailored specifically for gene therapies, creating hurdles in approval pathways and clinical research.
The shortage of skilled professionals trained in gene editing technologies and the absence of standardized manufacturing protocols further delay commercialization. Infrastructure constraints such as limited bioprocessing facilities and insufficient cold chain networks for biologics also pose logistical bottlenecks. Moreover, ethical and safety concerns—especially with germline editing—continue to draw scrutiny from policymakers and the public. Patient recruitment for clinical trials remains difficult due to low awareness and limited access in rural areas. Addressing these systemic issues will be critical to ensuring equitable and sustainable market expansion.
Segmentation
India Gene Therapy Market, By Indication:
India Gene Therapy Market, By Vector Type:
India Gene Therapy Market, By Route of Administration:
Regional Analysis
South India, particularly Bengaluru and Hyderabad, is a leading hub for gene therapy research and development, contributing approximately 40% of the market’s R&D activity in 2025. These cities host premier biotechnology parks, such as Genome Valley in Hyderabad, which houses over 200 biotech firms, and Bangalore Bioinnovation Centre, supporting 50 gene therapy startups. The Centre for Cellular and Molecular Biology (CCMB) and National Institute of Animal Biotechnology (NIAB) in Hyderabad have driven 30% of India’s gene therapy patent filings (400 out of 1,300 patents in 2023–2025), focusing on therapies for thalassemia and sickle cell anemia, affecting 100,000 and 1.5 million individuals, respectively. South India’s 75,000 skilled life science professionals, with a 10% annual increase in biotech graduates, further bolster innovation.
North India, led by Delhi-NCR and Chandigarh, accounts for 30% of the market, excelling in clinical trials and diagnostics. The All India Institute of Medical Sciences (AIIMS) Delhi and the Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh conducted 15 gene therapy trials in 2024, targeting oncology (e.g., leukemia, with 65,000 new cases in 2024) and rare diseases like hemophilia (50,000 cases). AIIMS’s Centre for Excellence under the National Policy for Rare Diseases (NPRD) 2021 facilitated trials for spinal muscular atrophy (SMA), affecting 1 in 8,000 births. The region’s 150 advanced diagnostic labs, equipped with next-generation sequencing (NGS), increased genetic disorder detection by 25% in 2024, supporting early intervention.
West India, particularly Mumbai and Pune, contributes 25% to the market, driven by a strong pharmaceutical presence and venture capital activity. Companies like Intas Pharmaceuticals and Serum Institute of India in Pune have invested ₹1,200 crore in gene therapy R&D since 2023, with five CAR-T cell therapy trials for lymphoma underway in 2025. Mumbai’s venture capital ecosystem funded 20 biotech startups with ₹800 crore in 2024, enabling technology transfers from global firms like Novartis. Maharashtra’s 40% share of India’s pharma exports supports the establishment of three viral vector manufacturing units, critical for gene therapy delivery, in Pune by 2025.
East and North-East India, with a 5% market share, lag due to limited infrastructure and a shortage of skilled professionals, with only 10% of India’s biotech workforce located here. However, government initiatives like the Department of Biotechnology (DBT)’s biotech clusters in Kolkata and Guwahati are bridging the gap, with ₹150 crore invested in 2024 to establish genomic research facilities. These clusters aim to address diseases like sickle cell anemia, prevalent in Odisha’s tribal populations (15% prevalence). The region conducted three gene therapy trials in 2024, primarily for hemoglobinopathies, supported by DBT’s ₹50 crore funding for rare disease research.
Incentives in Key States:
States like Gujarat and Maharashtra have introduced incentives, such as 50% subsidies on biotech infrastructure and tax breaks, attracting ₹2,000 crore in investments for gene therapy facilities in 2023–2024. Gujarat’s GIFT City launched a biotech SEZ in 2024, hosting two vector manufacturing units. Urban regions with robust medical infrastructure, such as Bengaluru (150 hospitals) and Delhi-NCR (200 hospitals), are expected to drive near-term growth at a CAGR of 23% through 2030. However, rural expansion, where 65% of India’s population resides, is critical for long-term sustainability. Initiatives like mobile diagnostic units, reaching 1 million rural patients in 2024, and DBT’s ₹100 crore investment in rural biotech outreach by 2026 aim to ensure equitable healthcare delivery.
Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=27691
Primary Catalysts and Hindrances
Catalysts: Rapid advancements in genomic medicine and falling costs of gene sequencing are propelling the gene therapy space in India. The availability of funding from government schemes like BIRAC and the Department of Biotechnology (DBT) has enabled early-stage companies to scale up. Additionally, India’s thriving biosimilars and biopharma ecosystem serves as a strong foundation for expanding gene therapy research. Technological collaboration with global pharma players allows access to novel delivery vectors and clinical platforms. Moreover, increasing public health awareness and advocacy by rare disease foundations are mobilizing both public and private support.
Hindrances: However, a lack of clear regulatory pathways for gene therapy continues to impede market progression. High development and manufacturing costs, coupled with low patient affordability, limit scalability. The need for GMP-compliant vector manufacturing facilities remains unmet, adding delays to clinical pipelines. Additionally, the social stigma around genetic diseases in certain regions prevents early diagnosis and trial participation. Intellectual property protection and biosafety oversight also remain underdeveloped, impacting investor confidence and innovation velocity.
Key Players and Market Analysis
The India Gene Therapy Market features a blend of multinational corporations and emerging domestic players actively contributing to R&D, manufacturing, and commercialization. Novartis India Ltd. remains a front-runner with its globally successful Zolgensma (for SMA), which has recently been introduced in India through patient access programs. The company is expanding collaborations with local distributors and clinicians to scale access.
Bharat Biotech, traditionally known for vaccines, is diversifying into gene-based platforms and currently supports several gene-modified immunotherapy research projects. Cipla Limited is investing in strategic partnerships with international biotech firms to explore CAR-T cell therapy and gene editing technologies. Zydus Group has made significant progress with its plasmid DNA-based therapeutics, particularly in oncology applications.
Biocon Limited and Dr. Reddy's Laboratories are leveraging their strong biosimilars portfolios to pivot toward gene therapies, particularly targeting oncology and autoimmune indications. Intas Pharmaceuticals Ltd. is building vector manufacturing capabilities to support future in-house clinical trials. Sun Pharmaceutical Industries Ltd., with its extensive global network, is actively evaluating in-licensing options for gene therapy candidates.
Serum Institute of India, while globally recognized for vaccines, is diversifying its portfolio into genetic platforms through subsidiaries and collaborative ventures. Panacea Biotec is exploring rare disease gene therapies, targeting partnerships to secure AAV vector technology.
Together, these companies represent a strategic mix of capital, infrastructure, and clinical expertise that is poised to elevate India’s role in global gene therapy innovation. Continued investment in infrastructure, regulatory clarity, and workforce development will define their competitive edge in the years to come.
Future Outlook
Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=27691
Recent Published Reports –
Medical Device Contract Manufacturing Market - https://www.techsciresearch.com/report/medical-device-contract-manufacturing-market/15029.html
Europe Hospital Market https://www.techsciresearch.com/report/europe-hospital-market/7691.html
Turkey Pharmaceuticals Market https://www.techsciresearch.com/report/turkey-pharmaceutical-market/14932.html
Germany Adult Day Care Software Market https://www.techsciresearch.com/report/germany-adult-day-care-software-market/29458.html
Pet Bird Health Market - https://www.techsciresearch.com/report/pet-bird-health-market/29459.html
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Website: https://www.techsciresearch.com
Rare Disease Gene Therapy Market: SnapshotThe global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide.
These kids are expected to experience complex clinical issues in the wake of getting live-sparing bone marrow transfers to treat the condition.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=80404The report offers insights into the market emphasizing on factors boosting, repelling, challenging, and creating opportunities for the market in the forecast period.
In terms of indication, the market is grouped into inflammatory diseases, neurological diseases, infectious diseases, hematology diseases, oncology diseases, genetic diseases, and others.
What's more, clinical-stage improvement organizations are allotting critical assets towards the advancement of the uncommon illness quality treatment market.For example, in August 2020, the U.S. based Ovid Therapeutics teamed up with Italian firm Angelini Pharma to create, make and popularize drug gaboxadol for treatment of Angelman disorder (uncommon hereditary sickness) in European market.Some of the players of the global rare disease gene therapy market include Amgen Inc., AbbVie Inc., F.Hoffmann-La Roche Ltd., Merck & Co., Johnson & Johnson, Baxter, Novo Nordisk A/S, Alexion, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Allergen plc., Vertex Pharmaceuticals, and others.Request Customization on Rare Disease Gene Therapy Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=80404Rare Disease Gene Therapy Market: Interesting InsightsThere has been an intense competition among biopharmaceutical players to create Covid treatment that is postponing on account of innovative work exercises in uncommon infection quality treatment market.
Stop of assembling exercises and flexibly tie disturbance because of exchanging across outskirts will have sway on uncommon illness quality treatment market development rate.
Also, clinical-stage advancement organizations are allotting critical assets towards the improvement of the uncommon infection quality treatment market.Pre Book Rare Disease Gene Therapy Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=80404=S Rare Disease Gene Therapy Market: Regional CategorizationNorth America will keep on overwhelming the uncommon illness quality treatment market in the coming decade with a high pace of endorsements and commercialization of genomic medication.
